You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School

Last Updated: February 25, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Carnosine

Email this page to a colleague

See Plans and Pricing

« Back to Dashboard

What is the drug development status for Carnosine?

Carnosine is an investigational drug.

There have been 12 clinical trials for Carnosine. The most recent clinical trial was a Phase 2 trial, which was initiated on October 1st 2018.

The most common disease conditions in clinical trials are Hyperuricemia, Schizophrenia, and Peripheral Arterial Disease. The leading clinical trial sponsors are China Medical University Hospital, Monash University, and University of Pittsburgh.

There is one US patent protecting this investigational drug and nine international patents.

Recent Clinical Trials for Carnosine
Carnosine for Peripheral Vascular DiseaseMonash HealthPhase 2
Carnosine for Peripheral Vascular DiseaseMonash UniversityPhase 2
Efficacy of Zinc L-carnosine in Maintaining Remission of Gastroesophageal Reflux DiseaseIRCCS Policlinico S. MatteoPhase 4

See all Carnosine clinical trials

Clinical Trial Summary for Carnosine

Top disease conditions for Carnosine
Top clinical trial sponsors for Carnosine

See all Carnosine clinical trials

US Patents for Carnosine

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Carnosine   Start Trial Compositions and methods useful for ameliorating age related maladies NestecSA (Vevey, CH)   Start Trial
Carnosine   Start Trial Bioeffective krill oil compositions AKER BIOMARINE ANTARCTIC AS (Stamsund, NO)   Start Trial
Carnosine   Start Trial Dyeing process using a mixture obtained from an aerosol device comprising a glycerolated surfactant, and device therefor L'OREAL (Paris, FR)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.